Cargando…

HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy

The role of HCV on the HIV reservoir is controversial since the reduction on HIV-DNA levels after HCV eradication with IFNα/RBV treatment seems to be the result of drugs instead of HCV clearance. We assessed whether HCV eradication can decrease HIV-DNA content in HIV/HCV-coinfected patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Álvarez, Beatriz, Navarrete-Muñoz, María A., Briz, Veronica, Olmedillas-López, Susana, Nistal, Sara, Cabello, Alfonso, Prieto, Laura, Górgolas, Miguel, García-Arranz, Mariano, Benito, José M., Rallón, Norma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948254/ https://www.ncbi.nlm.nih.gov/pubmed/35332180 http://dx.doi.org/10.1038/s41598-022-08871-0

Ejemplares similares

Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients
por: Álvarez, Beatriz, et al.
Publicado: (2020)

HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells
por: Rallón, Norma, et al.
Publicado: (2017)

Both HCV Infection and Elevated Liver Stiffness Significantly Impacts on Several Parameters of T-Cells Homeostasis in HIV-Infected Patients
por: Restrepo, Clara, et al.
Publicado: (2020)

Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
por: de Gennaro, Nicolò, et al.
Publicado: (2020)

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation
por: Grottenthaler, Julia M., et al.
Publicado: (2018)

Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients
por: Medrano, Luz M., et al.
Publicado: (2016)

HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study
por: López-Huertas, Maria Rosa, et al.
Publicado: (2019)

Expression of PD-1 and Tim-3 markers of T-cell exhaustion is associated with CD4 dynamics during the course of untreated and treated HIV infection
por: Rallón, Norma, et al.
Publicado: (2018)

Dynamics of HIV Reservoir and HIV-1 Viral Splicing in HCV-Exposed Individuals after Elimination with DAAs or Spontaneous Clearance
por: Martínez-Román, Paula, et al.
Publicado: (2022)

Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy
por: Colombatto, Piero, et al.
Publicado: (2022)

High frequency of CD8 escape mutations in elite controllers as new obstacle for HIV cure
por: Navarrete-Muñoz, María A., et al.
Publicado: (2022)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience
por: Marino, Andrea, et al.
Publicado: (2021)

Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects
por: Zuccalà, Paola, et al.
Publicado: (2022)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
por: Casey, Julia L., et al.
Publicado: (2019)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients
por: Salmon, Dominique, et al.
Publicado: (2018)

Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection
por: Chuaypen, Natthaya, et al.
Publicado: (2023)

No impact of IL28B polymorphisms on liver enzymes in patients coinfected with HIV and HCV
por: Fernández-Montero, JV, et al.
Publicado: (2010)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients
por: Ménard, A, et al.
Publicado: (2014)

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
por: Walker, David R., et al.
Publicado: (2015)

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data
por: Chen, Zhi-wei, et al.
Publicado: (2016)

Peripheral T follicular helper Cells Make a Difference in HIV Reservoir Size between Elite Controllers and Patients on Successful cART
por: García, Marcial, et al.
Publicado: (2017)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure
por: Danishwar, Mahmood, et al.
Publicado: (2022)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
por: Fabrizi, Fabrizio, et al.
Publicado: (2021)

Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
por: Brothers, Sarah, et al.
Publicado: (2022)

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort
por: d'Arminio Monforte, Antonella, et al.
Publicado: (2017)

P1096: TREATMENT OF HEPATITIS C-ASSOCIATED MARGINAL ZONE LYMPHOMA(HCV+LMZ) WITH DIRECT-ACTING ANTIVIRAL DRUGS (DAAS)
por: Lepkov, Sergey, et al.
Publicado: (2023)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021)

ADAM10 Gene Polymorphism and Its Relationship to Hepatocellular Carcinoma in Egyptian HCV Patients Receiving Direct-Acting Antiviral Therapies (DAAs)
por: Ghanem, Samar, et al.
Publicado: (2023)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV–HCV Coinfected Patients
por: Tripathi, Gaurav, et al.
Publicado: (2022)

Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection
por: Pinchera, Biagio, et al.
Publicado: (2023)

COVID-19 in people living with HIV: A multicenter case-series study
por: Cabello, Alfonso, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v6ckll39ocpvno5iiejb319p9n